On November 12, the Asia -Pacific Pharmaceutical closed at 3.66 yuan today, an increase of 3.10%, and the latest city net rate was 5.38, a new low in 154 days.
In terms of capital flow, on November 12, the net inflow of the main funds of Asia -Pharmaceuticals was 11.8402 million yuan. In the past 5 days, the overall flow was inflow, and a total of 309,100 yuan was inflow on the 5th.
Zhejiang Asia Pacific Pharmaceutical Co., Ltd. is mainly engaged in pharmaceutical manufacturing business, including the development, production and sales of chemicals, chemicals and drugs.The main products of the company include anti-amoxicillinocravate decentralized tablets, dispersing tablets, injection of Azithromycin, romamin capsules, and sodium cephalopirazolizer.Ronamin capsules, cephalosporin ammonia capsules, Achigromycin decentralized tablets and injection with Azithromycin as the leading product of the company.
The latest performance shows that in the third quarter of 2024, the company realized operating income of 307 million yuan, 1.65%year-on-year; net profit-3459530.47 yuan, a year-on-year-year-on-year gross profit margin of 31.10%.
This article comes from: the financial industry
Author: market
